Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update

Published: Mar 18, 2013

LAWRENCEVILLE, N.J., March 18, 2013 -- /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced financial results for the year ended December 31, 2012, and provided an update on its clinical trials of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin.

Back to news